SeekingAlpha article answers unbalanced Ryan Vanzo hatchet job:
Opko Health - CEO Buybacks Are Just The Beginning
Key points include:
- "Financial statements in early 2012 indicate that Opko Health has no liquidity problems, with total liabilities being a small percentage of total cash. ...filings indicate that Opko Health's annual burn rate of less than $30 million is less than 2% of the market capitalization of the $1.43 billion company"
- "Shares of Opko Health have outperformed the S&P 500 Index by over 20% over the past 12 months. This strength is attributable to several factors, including the current state of worldwide diagnostic cancer needs and Opko Health's focus on capitalizing on entrenched inefficiencies of in-office patient care."
- "Opko Health's cancer diagnosis wing and the recent modernization of its instrumentation wing have boosted the demand for the company's products across the world. Cash flow has been improving on a quarterly basis over the past year, and the company now employs over 200 full-time staff who generate over $30 million in annual revenues."
- "Dr. Frost has bought over $20 million shares of common stock in the past year alone and owns over 110 million shares, continuing to add more shares almost every week. Investors know that Dr. Frost is worth over $2 billion personally--more than the entire market capitalization of Opko Health--and his appetite for buying shares for his personal account is apparently not declining. Indeed, he already owns around half the company's shares."
- "The most important aspects of Opko Health remain--as with any pharmaceutical company--in its actual portfolio: Doxovir, Peptoides, Aquashunt, SCH 900978, H1N1/H5H1 flu vaccines, and diagnostic kits for cancer and Alzheimer's diseases."
SeekingAlpha article: Opko Health - CEO Buybacks Are Just The Beginning
26-Mar-12 11:30 am The article is a powerful counterpoint to the previous unbalanced SeekingAlpha article by another writer. Key points include:
- "Financial statements in early 2012 indicate that Opko Health has no liquidity problems, with total liabilities being a small percentage of total cash. ...filings indicate that Opko Health's annual burn rate of less than $30 million is less than 2% of the market capitalization of the $1.43 billion company"
- "Shares of Opko Health have outperformed the S&P 500 Index by over 20% over the past 12 months. This strength is attributable to several factors, including the current state of worldwide diagnostic cancer needs and Opko Health's focus on capitalizing on entrenched inefficiencies of in-office patient care."
- "Opko Health's cancer diagnosis wing and the recent modernization of its instrumentation wing have boosted the demand for the company's products across the world. Cash flow has been improving on a quarterly basis over the past year, and the company now employs over 200 full-time staff who generate over $30 million in annual revenues."
- "Dr. Frost has bought over $20 million shares of common stock in the past year alone and owns over 110 million shares, continuing to add more shares almost every week. Investors know that Dr. Frost is worth over $2 billion personally--more than the entire market capitalization of Opko Health--and his appetite for buying shares for his personal account is apparently not declining. Indeed, he already owns around half the company's shares."
- "The most important aspects of Opko Health remain--as with any pharmaceutical company--in its actual portfolio: Doxovir, Peptoides, Aquashunt, SCH 900978, H1N1/H5H1 flu vaccines, and diagnostic kits for cancer and Alzheimer's diseases."
http://seekingalpha.com/article/457311-opko-health-ceo-buybacks-are-just-the-beginning?source=yahoo